BRCA2 and prostate carcinoma: It should be noted, however, that among the Icelandic population, the prevalence of BRCA2 mutations is about 8% (Arason et al, 1993, Thorlacius et al, 1996) and this may account for most of the excess prostate cancer risk in this population.